Standout Papers

Inaxaplin for Proteinuric Kidney Disease in Persons with Two <i>APOL1</i> Variants 2023 2026 202487
  1. Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants (2023)
    Ogo Egbuna, Brandon Zimmerman et al. New England Journal of Medicine

Immediate Impact

19 by Nobel laureates 16 from Science/Nature 64 standout
Sub-graph 1 of 22

Citing Papers

Computational approaches streamlining drug discovery
2023 StandoutNature
TTD: Therapeutic Target Database describing target druggability information
2023 Standout
3 intermediate papers

Works of Mark E. Bunnage being referenced

Applications of chemogenomic library screening in drug discovery
2017
Getting pharmaceutical R&D back on target
2011
and 2 more

Author Peers

Author Last Decade Papers Cites
Mark E. Bunnage 1244 1688 200 306 51 2.9k
Scott A. Biller 828 1478 175 139 53 2.7k
Russell C. Petter 1738 2049 177 170 60 3.9k
Paul V. Fish 636 1892 199 320 59 2.9k
Chris P. Miller 1189 1324 295 233 61 3.5k
Patrick A. Marcotte 782 1464 149 143 67 2.6k
Carl P. Decicco 1216 1339 258 169 99 3.3k
Julian Blagg 1141 1730 220 169 92 3.5k
Lawrence G. Hamann 1243 1734 156 114 63 4.1k
Jörg Benz 630 2798 360 161 64 4.2k
Andrew J. Souers 677 1963 99 350 77 3.1k

All Works

Loading papers...

Rankless by CCL
2026